MARKET

CARA

CARA

Cara
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.15
-0.38
-2.62%
After Hours: 14.15 0 0.00% 17:14 09/21 EDT
OPEN
14.44
PREV CLOSE
14.53
HIGH
14.46
LOW
13.89
VOLUME
330.06K
TURNOVER
--
52 WEEK HIGH
26.67
52 WEEK LOW
8.88
MARKET CAP
663.45M
P/E (TTM)
-5.6496
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Top Marijuana Stocks on the NASDAQ for September 2020
These are the marijuana stocks on the NASDAQ with the best value, fastest growth, and best performance for September.
Investopedia · 08/27 20:37
Here's What Cara Therapeutics, Inc.'s (NASDAQ:CARA) Shareholder Ownership Structure Looks Like
If you want to know who really controls Cara Therapeutics, Inc. (NASDAQ:CARA), then you'll have to look at the makeup...
Simply Wall St. · 08/27 14:55
Cara Therapeutics, Inc. (CARA) CEO Derek Chalmers on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/11 00:28
Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 08/10 23:05
Cara Therapeutics Reports Second Quarter 2020 Financial Results
GlobeNewswire · 08/10 21:01
Cara Therapeutics Q2 EPS $(0.54) Beats $(0.67) Estimate, Sales $5.63M Beat $5.06M Estimate
Cara Therapeutics (NASDAQ:CARA) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.67) by 19.4 percent. This is a 6.9 percent increase over losses of $(0.58) per share from
Benzinga · 08/10 20:31
Cara Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
GlobeNewswire · 08/06 21:01
Cara Therapeutics to Announce Second Quarter 2020 Financial Results on August 10, 2020
GlobeNewswire · 08/03 21:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CARA stock price target is 33.25 with a high estimate of 40.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 211
Institutional Holdings: 34.17M
% Owned: 72.88%
Shares Outstanding: 46.89M
TypeInstitutionsShares
Increased
46
2.57M
New
55
-897.11K
Decreased
27
1.15M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.94%
Pharmaceuticals & Medical Research
-2.24%
Key Executives
President/Chief Executive Officer/Director
Derek Chalmers
Senior Vice President/Chief Scientific Officer
Frederique Menzaghi
Chief Compliance Officer/General Counsel/Secretary
Scott Terrillion
Vice President/Controller
Richard Makara
Other
Joana Goncalves
Lead Director/Independent Director
Martin Vogelbaum
Director
Susan Shiff
Independent Director
Harrison Bains
Independent Director
Jeffrey Ives
Independent Director
Christopher Posner
  • Dividends
  • Splits
  • Insider Activity
No Data

Analyst Price Target

The average CARA stock price target is 33.25 with a high estimate of 40.00 and a low estimate of 20.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CARA
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body's peripheral nervous system. The Company operates through the activities related to the discovery and development of therapeutics to treat serious medical conditions, including pain and pruritus. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845 for acute and chronic pain, and CR701 for neuropathic and inflammatory pain. I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. CR845 has exhibited anti-pruritic, or anti-itch, potency in standard preclinical models.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cara Therapeutics Inc stock information, including NASDAQ:CARA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CARA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CARA stock methods without spending real money on the virtual paper trading platform.